This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
All content for Drug Target Review Podcast is the property of Drug Target Review and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
In this podcast episode, we will be investigating the key considerations in selecting an antibody for use in antibody drug conjugates (ADCs). Also, we will be discussing the preclinical models used to evaluate the pharmacokinetics and pharmacodynamics of ADCs.
This conversation features Dr Philipp Spycher, CSO and co-founder at Araris Biotech, and Dr Rebecca Boohaker, Director of Oncology at Southern Research.
Drug Target Review Podcast
This episode, 'Plasmids: Tackling Supply Chain and Manufacturing Challenges,' explores the critical supply chain and manufacturing hurdles impacting the life science industry, especially in gene therapy. We'll uncover effective strategies for securing plasmids of the necessary grades, vital for advancing life-changing treatments.
Join us as we speak with Matthew Hewitt, Vice President and Technical Officer for CGT & Biologics at Charles River Laboratories.
Matthew will explore:
- Strategies for providing plasmids across all necessary grades, ensuring quality and consistency.
- How process standardization can significantly simplify complex supply chains.
- The crucial role of maintaining larger material stocks to overcome long-lead time consumable issues.
- How these integrated approaches collectively streamline operations and accelerate gene therapy advancements.
- His expert insights on the future trajectory of gene therapy.
